Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A Randomized Controlled Trial

Journal of the American Medical Association

Volumn 285, Issue 21, 2001, Pages 2719-2728

  Agodoa, Lawrence Y ^a   Appel, Lawrence ^a   Bakris, George L ^a   Beck, Gerald ^a   Bourgoignie, Jacques ^a   Briggs, Josephine P ^a   Charleston, Jeanne ^a   Cheek, DeAnna ^a   Cleveland, William ^a   Douglas, Janice G ^a   Douglas, Margaret ^a   Dowie, Donna ^a   Faulkner, Marquetta ^a   Gabriel, Avril ^a   Gassman, Jennifer ^a   Greene, Tom ^a   Hall, Yvette ^a   Hebert, Lee ^a   Hiremath, Leena ^a   Jamerson, Kenneth ^a   Johnson, Carolyn J ^a   Kopple, Joel ^a   Kusek, John ^a   Lash, James ^a   Lea, Janice ^a   Lewis, Julia B ^a   Lipkowitz, Michael ^a   Massry, Shaul ^a   Middleton, John ^a   Miller, Edgar R ^a   Norris, Keith ^a   O'Connor, Daniel ^a   Ojo, Akinlou ^a   Phillips, Robert A ^a   Pogue, Velvie ^a   Rahman, Mahboob ^a   Randall, Otelio S ^a   Rostand, Stephen ^a   Schulman, Gerald ^a   Smith, Winifred ^a   Thornley Brown, Denyse ^a   Tisher, C Craig ^a   Toto, Robert D ^a   Wright, Jackson T ^a   Xu, Shichen ^a   more..

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEGRO; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 0035816018     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.21.2719     Document Type: Article

References (40)

1. Blood pressure and end-stage renal disease in men
2. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy
3. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
4. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
5. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate risk of terminal renal failure in proteinuric non-diabetic nephropathy
6. Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies
7. Pathophysiology and treatment implications of hypertension in the African-American population
8. Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy?
9. Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers
10. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR
11. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms
12. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans
13. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies
14. Preservation of renal function: The spectrum of effects by calcium-channel blockers
15. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy
16. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study
17. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study
18. Human blood pressure determination by sphygmomanometry
19. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study
20. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients
21. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease
22. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
23. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study
24. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
25. A multiple testing procedure for clinical trials
26. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
27. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
28. The effect of angiotensin-converting-enzyme inhibitors on the progression of non-diabetic renal disease: A pooled analysis of individual patient data from 11 randomized controlled trials
29. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass
30. Class differences in the effects of calcium channel blockers in the rat remnant kidney model
31. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR
32. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy
33. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus
34. Analysis of change in the presence of informative censoring: Application to to longitudinal clinical trial of progressive renal disease
35. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
36. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: A progress report on the Syst-China trial
37. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial
38. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials